Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2018

View Archived Issues

Convert Pharmaceuticals secures funding to advance lead cancer drug

First infant treated in Longeveron's mesenchymal stem cell therapy trial

Concert selects CTP-692 for development as adjuvant treatment for schizophrenia

FDA grants breakthrough therapy designation for GC-4419 for the reduction of severe oral mucositis

Innovimmune Biotherapeutics' INV-25 reduces tumor growth in vivo

Heat Biologics announces positive results from phase II trial of HS-110 for NSCLC

Patients being enrolled in phase II study of JNJ-56136379 for chronic HBV infection

FDA fast track designation granted to Fibrogen's pamrevlumab for unresectable pancreatic cancer

Initiation of phase II study of BMS-986263 in subjects with advanced hepatitis fibrosis

Dong-A begins first-in-human trial of botanical drug candidate DA-9805

Novartis presents novel SPPL2a inhibitor as a potent immunomodulator

Patient enrollment ongoing in AstraZeneca's phase II study of AZD-8601

Phase II study of IRL-790 is enrolling patients with Parkinson's disease dyskinesia

TES Pharma creates first potent and selective inhibitor of human ACMSD

Sublocade becomes available as first and only monthly injectable buprenorphine in the U.S.

Antisense Therapeutics gains ethics approval to begin phase II trial of ATL-1102 in DMD

Qingdao Marine Biomedical Research Institute patents new ER stress inhibitors

Neomed Institute launches spin-out Neomed Therapeutics 1

Shenzhen Targetrx Biotechnology divulges BTK inhibitors

Positive results from bioequivalence study of Biohaven's rimegepant Zydis orally dissolving tablets

Novel DGAT2 inhibitors presented by Pfizer

FDA accepts for review Dupixent sBLA for moderate to severe asthma

Verona announces phase IIa topline data for RPL-554 in cystic fibrosis

French researchers present novel NMDA receptor agonists

Merck & Co. patents new CYP8B1 inhibitors

Reata releases data from phase II trial of omaveloxolone in patients with mitochondrial myopathies

Acumen selects Avid Bioservices for process development, manufacturing of Alzheimer's candidate

FDA accepts Remoxy ER NDA

IRP1 targeting ameliorates Chuvash polycythemia in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...